Corbus Pharmaceuticals Holdings Inc (CRBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.08-3.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRBP — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Sec…
Why it matters: Data on this combination therapy could help with more trials. It may change CRB-701's market chance.
Watch forPositive data from the CRB-701 and Keytruda combination in 1L OPSCC is due in Q1 2027.
Also watch forNegative data from the combination therapy is due in Q1 2027.
Why it matters: How management handles the earnings miss will show their plan. This will affect investor trust.
Worry ifManagement provides a clear plan to address the earnings miss in the next earnings call.
Less concerning ifManagement does not explain the earnings miss. They give unclear answers.
Why it matters: Starting this study is a key step toward potential FDA approval. It signals progress in Corbus's oncology pipeline.
Supportive ifThe registrational study for CRB-701 in 2L OPSCC begins as planned this summer.
Worry ifThe study is delayed or not initiated as scheduled.
Why it matters: The earnings report will reveal if the company is improving its financial situation. Investors will look for signs of recovery.
Watch forQ2 revenue growth exceeds 10% year over year, indicating a positive trend.
Also watch forQ2 revenue is down compared to last year. This shows ongoing money problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$204 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $716 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,188 loss on $10,000 · 61.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Ongoing FDA discussions may clarify the path for CRB-701's approval. Clear guidance can enhance development confidence.
Watch forThe FDA gave good news. It matches what management expected.
Also watch forNegative feedback from the FDA that complicates the approval path for CRB-701.
Why it matters: The ASCO presentation will share new data on CRB-701's performance. This affects its market potential.
Supportive ifNew CRB-701 data at ASCO 2026 shows strong results for efficacy and safety.
Worry ifThe data shows low effectiveness or safety issues. This could hurt investor trust.
Why it matters: These results will show CRB-913's potential as a new treatment for obesity. Positive data could increase market interest.
Supportive ifTopline data from the CANYON-1 study shows significant weight loss results after 16 weeks.
Worry ifTopline data shows minimal or no weight loss results after 16 weeks.
Why it matters: Starting enrollment in this Phase 3 study is a key step for CRB-701 in oropharyngeal cancer.
Supportive ifEnrollment in the TEMPO-1 study begins in September 2026 as planned.
Worry ifEnrollment does not start as scheduled or is delayed beyond September 2026.
Why it matters: Data from this obesity study will show how well CRB-913 works for weight loss.
Supportive ifTopline data from the CANYON-1 Phase 1b study is reported in September 2026.
Worry ifData is not reported or is delayed past September 2026.
Why it matters: Knowing cash burn will help us see if the company can keep running until 2028.
Worry ifOperating costs stay the same or go down compared to earlier quarters.
Less concerning ifOperating costs rise a lot above current levels, showing higher cash burn.